| A CFTR potentiator in patients with cystic fibrosis and the G551D mutation BW Ramsey, J Davies, NG McElvaney, E Tullis, SC Bell, P Dřevínek, ... New England Journal of Medicine 365 (18), 1663-1672, 2011 | 2513 | 2011 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2084* | 2021 |
| Disordered microbial communities in asthmatic airways M Hilty, C Burke, H Pedro, P Cardenas, A Bush, C Bossley, J Davies, ... PloS one 5 (1), e8578, 2010 | 2044 | 2010 |
| Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR CE Wainwright, JS Elborn, BW Ramsey, G Marigowda, X Huang, M Cipolli, ... New England Journal of Medicine 373 (3), 220-231, 2015 | 1623 | 2015 |
| The future of cystic fibrosis care: a global perspective SC Bell, MA Mall, H Gutierrez, M Macek, S Madge, JC Davies, PR Burgel, ... The Lancet Respiratory Medicine 8 (1), 65-124, 2020 | 928 | 2020 |
| Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation JC Davies, CE Wainwright, GJ Canny, MA Chilvers, MS Howenstine, ... American journal of respiratory and critical care medicine 187 (11), 1219-1225, 2013 | 634 | 2013 |
| Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial E Alton, M Stern, R Farley, A Jaffe, SL Chadwick, J Phillips, J Davies, ... The Lancet 353 (9157), 947-954, 1999 | 566 | 1999 |
| Tezacaftor–ivacaftor in residual-function heterozygotes with cystic fibrosis SM Rowe, C Daines, FC Ringshausen, E Kerem, J Wilson, E Tullis, N Nair, ... New England Journal of Medicine 377 (21), 2024-2035, 2017 | 536 | 2017 |
| Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial EWFW Alton, DK Armstrong, D Ashby, KJ Bayfield, D Bilton, ... The Lancet Respiratory Medicine 3 (9), 684-691, 2015 | 527 | 2015 |
| Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence JC Davies Paediatric respiratory reviews 3 (2), 128-134, 2002 | 457 | 2002 |
| CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression SC Hyde, IA Pringle, S Abdullah, AE Lawton, LA Davies, A Varathalingam, ... Nature biotechnology 26 (5), 549-551, 2008 | 376 | 2008 |
| VX-659–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles JC Davies, SM Moskowitz, C Brown, A Horsley, MA Mall, EF McKone, ... New england journal of medicine 379 (17), 1599-1611, 2018 | 359 | 2018 |
| Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study JC Davies, S Cunningham, WT Harris, A Lapey, WE Regelmann, ... The Lancet Respiratory Medicine 4 (2), 107-115, 2016 | 354 | 2016 |
| Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial F Ratjen, C Hug, G Marigowda, S Tian, X Huang, S Stanojevic, CE Milla, ... The lancet Respiratory medicine 5 (7), 557-567, 2017 | 342 | 2017 |
| Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis AR Horsley, PM Gustafsson, KA Macleod, C Saunders, AP Greening, ... Thorax 63 (2), 135-140, 2008 | 287 | 2008 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 269 | 2022 |
| Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled … J Davies, H Sheridan, N Bell, S Cunningham, SD Davis, JS Elborn, ... The lancet Respiratory medicine 1 (8), 630-638, 2013 | 269 | 2013 |
| Ivacaftor treatment of cystic fibrosis in children aged 12 to< 24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study M Rosenfeld, CE Wainwright, M Higgins, LT Wang, C McKee, D Campbell, ... The lancet respiratory medicine 6 (7), 545-553, 2018 | 261 | 2018 |
| Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane A Sabnis, KLH Hagart, A Klöckner, M Becce, LE Evans, RCD Furniss, ... elife 10, e65836, 2021 | 259 | 2021 |
| The Th17 pathway in cystic fibrosis lung disease HL Tan, N Regamey, S Brown, A Bush, CM Lloyd, JC Davies American journal of respiratory and critical care medicine 184 (2), 252-258, 2011 | 259 | 2011 |